Has Alison Fischer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,460,555 in general payments to Alison Fischer, MD across 1,184 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alison Fischer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alison Fischer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alison Fischer, MD

Dermatology · Tulsa, OKNPI 1225266307

Payments from drug & device makers

$1,460,555in general payments, 2019–2025

Across 1,184 payments — averaging $1233.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$800K
UCB SA$362K
Amgen$213K
Eli Lilly$68K
Boehringer Ingelheim$4K
Johnson & Johnson$2K
plus $13K from 38 others

$16,970in research payments, 2019–2025

Across 3 payments — averaging $5656.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$12K
Eli Lilly$5K

What the payments were for

Food & beverage$17,23495%
Education$8535%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	309	$800,135
UCB SA	44	$361,511
Amgen	55	$213,286
Eli Lilly	4	$67,678
Boehringer Ingelheim	5	$3,663
Johnson & Johnson	72	$1,629
Regeneron Healthcare Solutions, Inc.	60	$1,443
Pfizer	72	$1,130
Sun Pharmaceutical Industries Inc.	49	$1,025
Lilly USA, LLC	56	$1,000
Novartis	57	$913
LEO Pharma Inc.	53	$840
E.r. Squibb & Sons, L.L.C.	37	$698
UCB, Inc.	58	$691
Sanofi	25	$660
Mayne Pharma Commercial LLC	38	$569
Galderma Laboratories, L.p.	39	$465
Incyte Corporation	20	$431
Ortho Dermatologics, A Division Of Bausch Health US, LLC	22	$415
Kerecis Limited	5	$336
Arcutis Biotherapeutics, Inc.	23	$278
Organogenesis Inc.	10	$268
Dermavant Sciences, Inc.	11	$244
VYNE Pharmaceuticals Inc.	7	$175
Prugen, Inc. Pharmaceuticals	6	$148
Springworks Therapeutics, Inc.	1	$121
Almirall LLC	6	$111
Genentech USA, Inc.	7	$105
Strata Skin Sciences, Inc.	8	$102
Kyowa Kirin, Inc.	4	$89
Dermira, Inc.	3	$66
Revance Therapeutics, Inc.	1	$59
Celltrion USA Inc.	2	$42
Sandoz	2	$33
Fresenius Kabi USA, LLC	2	$30
Organon	3	$26
Journey Medical Corporation	1	$23
Mylan Pharmaceuticals Inc.	1	$22
Bristol Myers Squibb	1	$20
Sebela Pharmaceuticals Inc.	1	$18
Aclaris Therapeutics, Inc.	1	$16
Conmed Corporation	1	$15
Promius Pharma LLC	1	$15
Paratek Pharmaceuticals, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,460,555 in reported general payments places this provider in the 95th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$921,717

Medicare patients

866

Services billed

7,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	11	$177,274
Dupixent PenDupilumab	19	$73,139
Fluorouracil	58	$4,384
Tacrolimus	17	$2,378
Clobetasol Propionate	37	$2,226
Ketoconazole	72	$1,237
Doxycycline Hyclate	59	$942
Triamcinolone Acetonide	69	$925
Betamethasone Dipropionate	17	$630
Mupirocin	55	$455
Cephalexin	45	$401
Minocycline Hcl	22	$396
ValacyclovirValacyclovir Hcl	12	$209
MethotrexateMethotrexate Sodium	17	$205
Minoxidil	16	$196

Paid to pharmacies, not to this prescriber.

Other dermatology in Tulsa

George MonksTulsa$530K
Kristen RiceTulsa$57K
Jeff AlexanderTulsa$41K
Johnathan LedetTulsa$37K
John AshleyTulsa$24K
Mark LehmanTulsa$17K
Kelli LovelaceTulsa$14K
Bernard RobinowitzTulsa$14K
Christina KendrickTulsa$13K
Ashwini VaidyaTulsa$12K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →